References
- Shander A, Cappellini MD, Goodnough LT. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang 2009;97:185-97
- Poggiali E, Cassinerio E, Zanaboni L, et al. An update on iron chelation therapy. Blood Transfus 2012;10:411-22
- Shander A, Sazama K. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion 2010;50:1144-55
- Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001;1:47-61
- Abetz L, Baladi J-F, Jones P, et al. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes 2006;4:73-9
- Delea TE, Hagiwara M, Thomas SK, et al. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Am J Hematol 2008;83:263-70
- Novartis. Desferal Prescribing Information. 2016. United States. Available online at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/desferal.pdf. [Last accessed Sept 2016]
- ApoPharma. Ferriprox Prescribing Information. United States. Available online at: http://www.ferriprox.com/us/pdf/ferriprox_full_pi_solution.pdf. [Last accessed Sept 2016]
- Novartis. Exjade Prescribing Information. 2016. United States. Available online at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/exjade.pdf. [Last accessed Sept 2016]
- Novartis. Jadenu Prescribing Information. 2016. United States. Available online at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/jadenu.pdf. [Last accessed Sept 2016]
- Porter JB, Evangeli M, El-Beshlawy A. Challenges of adherence and persistence with iron chelation therapy. Int J Hematol 2011;94:453-60
- Trachtenberg F, Vichinsky E, Haines D, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol 2011;86:433-6
- Walsh KE, Cutrona SL, Kavanagh PL, et al. Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics 2014;134:1175-83
- Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007;47:1919-29
- Jordan LB, Vekeman F, Sengupta A, et al. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease. J Clin Pharm Ther 2012;37:173-81
- Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146-56
- Taher AT, Origa R, Perrotta S, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: results of the randomized, phase II ECLIPSE study. Am J Hematol 2017;92:420-8
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
- Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
- Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics 2007;25:329-42
- Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
- Chalmers AW, Shammo JM. Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Ther Clin Risk Manag 2016;12:201-8
- Martin LR, Williams SL, Haskard KB, et al. The challenge of patient adherence. Ther Clin Risk Manag 2005;1:189-99
- Germing U, Kobbe G, Haas R, et al. Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int 2013;110:783-90
- Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 2011;9:11-23